Search results for: Multi-Indication Medicines
Filter search results
NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?
30 July 2020
…The ‘optimisation’ of NICE TA recommendations is becoming more common The National Institute for Health and Care Excellence (NICE) makes recommendations for use of interventions including medicines in the National…
Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?
4 August 2020
…2016). Why the UK needs to get it right Within the UK, a particular concern is that the discounting rates applied differ between institutions. For interventions like medicines and diagnostics,…
How to Analyse EQ-5D Data? Methods for Analysing and Reporting EQ-5D Data: The Indispensable New Guide
8 December 2020
…recently – in routine data collection in health care systems. (…) EQ-5D has become the cornerstone of health technology appraisal (HTA), affecting important decisions about access to new medicines. But despite…
Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System
31 March 2021
In the contentious debate around US drug prices, less well understood is: if the price of a drug is a fair, value-based, price, how we assess if insurance coverage provides…
OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates
3 December 2021
US policymakers have been considering reforms to reduce drug spending, including allowing the government to directly set prices for branded medicines. Such policies would reduce global pharmaceutical revenues, leading to…
ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
6 June 2022
…indicated for rare diseases and as such, they face the same challenges as other orphan medicines. The aim of the panel was to discuss how HTA should evolve to enable…
Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
12 January 2013
…£12,936, as a result of NICE approving a new medicine, will lead to the loss of one quality-adjusted life-year (QALY). Therefore, they conclude, NICE should not approve medicines with a…
Value Based Pricing in Sweden: Lessons for Design?
11 January 2012
…in Sweden has been successful. It has avoided critics’ fears that the result would be rapid rises in medicines spending and has found mutually acceptable solutions for rewarding innovation and…
General Practice Today
1 July 1968
…time-consuming and heroic, if relatively ineffective, treatment. Now illness is often contained quickly before it becomes serious and is usually treated by the administration of effective medicines, such as antibiotics,…